University of California San Francisco
Give to UCSF
A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease.
In an achievement that has significant implications for research, medicine, and industry, UCSF scientists have genetically reprogrammed human immune cells without using viruses to insert DNA
UCSF researchers have identified a key biological pathway in human cancer patients that appears to prime the immune system for a successful response to immunotherapy drugs – checkpoint inhibitors.
Each year, 300,000 infants worldwide are born with sickle cell. UCSF Benioff Children’s Hospitals are at the the leading edge of advancements to cure sickle cell disease.
Silicon Valley is helping researchers like Wendell Lim move basic science breakthroughs into translational applications, making treatments available to patients faster than normally possible.
The journey from discovering and developing effective, precise medications to using them correctly and safely in patients is hardly fast and easy. Nor is it a straight shot. Scientists in the UCSF School of Pharmacy are challenging the status quo every step of the way.
UCSF researchers have safely transplanted a woman’s stem cells into her growing fetus, leading to the live birth of an infant with a normally fatal fetal condition.
UCSF neuroscientist identified the first potential treatment for the brain damage caused by exposure to cosmic rays.
UC San Francisco researchers have discovered a promising new line of attack against lethal, treatment-resistant prostate cancer.
UCSF scientists have uncovered new mechanisms by which HIV hides in infected cells, resting in a latent state that evades the body’s immune system and preventing antiviral drugs from flushing it out.
A new UCSF study has shown that a cancer-killing (“oncolytic”) virus currently in clinical trials may function as a cancer vaccine.
UCSF physician-scientists have developed a test that can predict how patients with juvenile myelomonocytic leukemia will respond to treatment.
Encellin obtained exclusive rights from UCSF for a proprietary cell encapsulation technology aimed at improving physicians’ ability to perform cell transplants without the need for immunosuppressive drugs.
Women who receive a breast cancer diagnosis while they are still young enough to bear children can take time to freeze their eggs and embryos without fear of delaying their cancer treatment.
